Abstract
The role of the transcription factor CCATT/enhancer binding protein alpha (C/EBPalpha) as a lineage instructive determinant in myelopoiesis is widely accepted. Furthermore, early mutational events ultimately leading to acute myeloid leukemia (AML) often involve abrogation of C/EBPalpha expression and/or function. The main focus of this review is the progression from a preclinical state to AML, and which preleukemic cell population(s) might-in general and in particular in patients with CEBPA mutations-be a target for the secondary genetic and epigenetic events leading to this progression. (c) 2009 International Union of Biochemistry and Molecular Biology, Inc.
Original language | English |
---|---|
Journal | BioFactors |
Volume | 35 |
Issue number | 3 |
Pages (from-to) | 227-31 |
Number of pages | 4 |
ISSN | 0951-6433 |
DOIs | |
Publication status | Published - 2009 |